We may finally see more streamlined approval of new drugs and devices, thanks to the U.S. Food and Drug Administration's latest effort to push researchers to use electronic health records in clinical trials--draft guidance published this week regarding how to use EHRs as a source of data. Still, the draft guidance is pretty skimpy and raises questions that must be answered.
The U.S. Food and Drug Administration has released draft guidance regarding the collection and use of electronic health record data in clinical trials.
Research involving technology-based interventions holds substantial potential to advance the speed of evidence-gathering to support healthcare delivery, according to an article at BMC Informatics and Decision-Making.
Use of platforms designed to provide access to individual patient data in order to increase transparency of clinical trial data has been limited, according to a research letter published in the Journal of the American Medical Association.
Recent developments in cancer treatment have hospitals increasingly on the hunt for top talent to aid in clinical trials, according to Capital New York.
Mobile health wearables aren't ready to play a starring role in clinical trials, according to Gartner Research Director Michael Shanler, despite all the attention the devices have seen recently.
The U.S. Food and Drug Administration, attempting to improve its clinical investigation processes, established a public docket last week to solicit feedback on how healthcare stakeholders are using technology for such research efforts.
University of Chicago researchers have developed a computational model to improve the allocation of U.S. biomedical research resources.
With the help of big data, researchers have discovered that the combination of two drugs can significantly lower patients' blood pressure, according to a study published in the Journal of General Internal Medicine.
Mobile healthcare tech adoption is lagging for more than a few reasons, writes health technology consultant David Lee Scher, M.D., despite the fact big name tech companies are investing in the market.